Table 1.
Examples of ligand and transcriptional targeting used in eukaryotic viral vectors in targeted cancer therapy.
| Vector | Tumor-Specific Promoters | Ligand Targeting | References |
|---|---|---|---|
| Ad | PSA, GH, TRE, rTG, AFP, VEGFR-2, flt-1, hTERT | RGD, NGR, SIGYPLP, CGKRK, SIKVAV | [13,15,16,17,18,19] |
| AAV | PRC1, RRM2, BIRC5 | NGR, GFE | [20,21] |
| HSV-1 | Albumin, ANGPTL-3, E2F-1 | ND * | [9,22] |
| LV | PSA/E | αCD20, hSCF | [17,23] |
| RV | CEA, GRP78, kdr, E-selectin | ND * | [17,24,25] |
| MV | ND * | HSNS, HAA | [26] |
AAV: adeno-associated virus; ANGPTL-3: human angiopoietin-like 3; BIRC5: Baculoviral IAP repeat-containing 5; E2F-1: transcription factor 1; GH: Growth hormone; PSA/E: Prostate-specific antigen/Enhancer; hSCF: human stem cell factor; HSNS/HAA: modified attachment protein H on MV; LV: lentivirus; MV: measles virus vector; PRC1: protein regulator of cytokinesis 1; RRM2: ribonucleotide reductase subunit 2; rTG: rat thyroglobulin; SIGYPLP, CGKRK, SIKVAV: homing peptides; RV: retrovirus; TRE: Tetracyclin response element; VEGFR2: Vascular endothelial growth factor receptor 2; * ND: Not determined.